Remove 2013 Remove Government Remove Provider Remove Specialization
article thumbnail

Gastroenterology Board Meeting Summary | Spring 2025

ABIM

The Specialty Board discussed the LKA in greater detail, as well as the use of artificial intelligence (AI) in assessment development and the integration of public members in ABIM Governance. Community Practice in ABIM Governance* Erica N. Blueprint Review Tool Ginneh Flamer, Ph.D.,

article thumbnail

Endocrinology, Diabetes and Metabolism Board Meeting Summary | Spring 2025

ABIM

See the discussion on the Special Consideration IMG (International Medical Graduates) Pilot Pathway below.) Community Practice in ABIM Governance* Erica N. Odelia Cooper, MD, Past-President of APDEM, asked how endocrinology fellowship programs can better prepare their graduates for board certification.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Infectious Disease Board Meeting Summary | Spring 2025

ABIM

Community Practice in ABIM Governance* Erica N. She also sought input on overlapping aspects of community practice across the disciplines of internal medicine to inform ABIM’s recruitment efforts for broad physician representation in governance roles.

article thumbnail

Nephrology Board Meeting Summary | Spring 2025

ABIM

Lieske, MD , raised concerns about how new government policies may affect international medical graduates and health equity work at ABIM. Community Practice in ABIM Governance* Erica N. Upgrades to the ABIM website and Physician Portal for 2025 designed to make it easier to find information for both physicians and the public.

article thumbnail

Does the Drug Shortage White Paper Fall Short?

FDA Law Blog

MRAP would provide oversight of an accreditation body which would conduct assessments—paid for by the manufacturer—based on criteria developed by the MRAP. Unfortunately, the White Paper does not provide further analysis on the generic sterile injectables and instead refers back to FDA’s analysis from 2013-2017. Section I.C